^
Association details:
| Biomarker: | IDH2 R172K |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Idhifa (enasidenib) (IDH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Enasidenib in Combination with Venetoclax in IDH2-Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial
Published date:
11/04/2021
Excerpt:
...11 patients were enrolled on study; 10 with R/R AML and 1 with very-high risk MDS by IPSS-R. Six patients had a R140Q mutation, and 5 had a R172K mutation....The preliminary efficacy of this combination is encouraging with an ORR of 55% in evaluable R/R AML patients…
Secondary therapy:
venetoclax
DOI:
10.1182/blood-2021-153660
